Concepedia

H. L. Kaiser

HL

4

Publications

100

Citations

4

H-Index

2008

Active since

Affiliations

Stanford Medicine(Current)

H. L. Kaiser is an author at Stanford Medicine specializing in cancer research, radiation oncology, and medicine.

Top concepts

MedicineOncologyCancer ResearchRadiation OncologyCancer TherapyPathologyPharmacologyPharmacotherapyMolecular OncologyNeuroendocrine Tumors

Publications per year

2008–2015

4

Publications

4

A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors.

P. L. Kunz, Tzu‐Ting Kuo, Jeffrey Zahn et al. · Journal of Clinical Oncology · 2010 · 47 citations

Endocrine Oncology, Oncology, Unresectable Neuroendocrine Tumors +14

A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors: Preliminary results

P. L. Kunz, Tzu‐Ting Kuo, H. L. Kaiser et al. · Journal of Clinical Oncology · 2008 · 30 citations

Angiogenesis Inhibition, Pathology, Phase Ii Study +18

Phase I trial of preoperative cetuximab in combination with oxaliplatin, capecitabine, and radiation therapy for locally advanced rectal cancer

Elwyn C. Cabebe, Tzu‐Ting Kuo, Albert C. Koong et al. · Journal of Clinical Oncology · 2008 · 13 citations

Adverse Events, Radiation Medicine, Radiation Therapy +14

Early Results: “ROCKET” a phase II Study of RRx-001, a novel triple epigenetic inhibitor, Resensitization to Irinotecan in Colorectal Cancer

C. Carter, T. Reid, George A. Fisher et al. · Annals of Oncology · 2015 · 10 citations

Gastrointestinal Oncology, Epigenetic Regulation, Medicine +8

Rows per page

1–4 of 4